FIELDS
SPECIALTY FIELDS | ACTIVE USERS |
Chiropractor | 24,761 |
Counselor Psychology | 87,493 |
Dentist (all types) | 36,690 |
Hospital Administrator | 17,365 |
Healthcare Administrator (other) | 84,556 |
Healthcare Executive (other) | 30,573 | Laboratory Technician | 19,055 |
Laboratory/Medical Technologist | 49,520 |
Nurse (all specialties) | 946,428 |
Nurse Practitioners (all specialties) | 150,060 |
Nutritionist / Dietitian | 49,091 |
Optometrist | 20,515 |
Paramedic/EMT | 124,693 |
Physical Therapist | 79,145 |
Physician Assistant (PA) (all specialties) | 95,430 |
Pharmacists (all types) | 187,996 |
Psychologists | 88,333 |
Radiology Technologist | 26,575 |
Rehab Specialist | 24,310 |
Social Worker | 74,787 |
Unmatched recruitment, advanced targeting, research solutions to meet your needs.
Meet the team.
Phone Number (optional)
Additional Details (optional)
Read McKinsey’s latest insights on the changes that matter most for navigating the future of healthcare.
Provider Insights | Payer Insights | Healthcare Services & Technology Insights | Business Building in Healthcare | Consumer Health Insights | Behavioral Health Insights | Public Health Insights
Featured article.
Most recent articles.
Featured collections.
Our conversations.
Provider insights.
Payer insights.
Healthcare services & technology insights.
Want to learn more about how we help clients in healthcare practice, business building in healthcare.
Consumer health insights.
Behavioral health insights.
Public health insights.
More insights.
Related practice.
Go through our vast portfolio of Pharmaceutical and MedTech reports.
Get comprehensive insights into the healthcare industry and epidemiology-based market forecasts with a 360° panoramic picture of the market alongside the latest trends, developments, and future opportunities.
With over 7000 research reports in the repository covering 27 therapeutic areas, stay updated about the most recent trends, news, and developments in the healthcare domain.
High quality market insights from our global panel of healthcare opinion leaders.
Ceo magazine, growthmix fieldwork.
Data collection methodology customized to your needs and consisting multiple approaches to high quality insights
Ground level insights on treatment flows, pricing and reimbursements, stakeholders mapping, product pipeline analysis and much more
Prescription Trends, Brand Recalls, Marketing Intelligence and much more through real time brand trackers
Gather expert insights and ground-level intelligence on target players
Unprecedented opinions. impeccable reliability., connecting healthcare leaders with organizations through world’s fastest growing healthcare knowledge exchange ecosystem.
GRG's maintains a database of healthcare experts globally with a significant representation of all specialties.
Through Growth+Connect we offer rapid introductions to global KOLs across various verticals for short and long term consultations. Our Growth+Connect leverages GRG's network of qualified opinion leaders and connects them with organizations around the world
Our GrowthMIX approach offers a custom mix of multiple methodologies suited to the complexity of the study
The Internet of Medical Things (IoMT) - GRG Health
Wearable Tech and Predictive Health Analytics: Revolutionizing Healthcare
Cracking the Gut Code: Understanding the Enigma of Irritable Bowel Syndrome
Understanding Opioid Usage: A Global Health Perspective
Cybersecurity in HealthTech: Protecting Patient Data in the Digital Age
Smart Contact Lenses: Beyond Vision Correction
Streamlining Hospital Operations: Best Practices for Data Leaders
Nanomedicine and Nanotechnology in Healthcare
Microbiome Research and Its Impact on Health and Disease
Kol identification and profiling, oncology intel book, logistics and procurement, health insurance research.
Our knowledge services offer on-going insights generation through dedicated teams and specialist driven process. GRG's knowledge archives and specialized processes of delivery helps clients scale and optimize their marketing intelligence initiatives.
Syndicated Healthcare Market Insights Reports Powered With Complimentary
Analyst Hours and Expert Interviews With Each Report
If you're a EPHMRA member and couldn’t attend you can access the conference videos here. If you would like more information get in touch with Ben...
Biotech takes on chronic weight management As Novo Nordisk and Lilly generate massive profits with weight-loss blockbusters Wegovy and Zepbound,...
ASCO 2024 ran from May 31-June 4 in Chicago, IL, bringing together physicians, academics, and industry to share data and discuss cutting edge...
Market Sizing And Forecast
Market Synthesis
Social Media Performance
Customized Ad-hoc Strategic Studies
futuriZm - A Peek Into The Future
Customized Ad-hoc Strategic studies
A peek into the future
Qualitative Deep-Dive Solution
Speed Testing For Go/No-go
Idea And Concept Testing
Product Mix Testing
Target Product Profile (TPP)
Advertisement And Communication
Brand Tracking And Brand Equity Measure
Awareness, Trial And Usage (ATU)
KOL Mapping
Customer Experience And Satisfaction
First Party Consumer, B2B And Healthcare Panels & Communities
SmartSight™ – Online Community Platform And Loyalty Management
Market Research Data Reporting: Multivariate Data Analytics
Competitive Intelligence And Voice Of Customer Platforms
Business Intelligence And Dashboards & Data Visualization
Industries/sectors we focus on ?
We have a strong lineage and proven capabilities across a range of industry verticals.
Advertising And Media
Automotive And Mobility
CPG And Retail
Travel And Tourism
Banking, Financial Services And Insurance
Food And Beverages & QSR
Healthcare And Life Science
Blog Fresh trends and insights
Case Studies Unveiling Success Stories
B2B Panel book Fresh trends and insights
B2C Panel book Fresh trends and insights
Healthcare Panel book Fresh trends and insights
B2B Panel book
B2C Panel book
Healthcare Panel book
About Borderless Access Our story, values & more
Leadership The faces behind Borderless Access
Awards & Affiliations Celebrating our commitment to excellence
Press Corner Our media coverage & events attended
CSR Corporate Social Responsibilty
Careers Build your career with us
Life at Borderless Access What sets us apart ?
Top Searches
Advertising & Media
CPG & Retail
Healthcare & Pharma
Healthcare, at its core, is about caring for people and improving lives. Borderless Access Health is dedicated to supporting worldwide healthcare brands by enhancing their comprehension of the landscape through healthcare market research, ultimately striving to enhance lives.
Borderless Access Health provides world-class healthcare market research services, offering a synergy of primary market research, business intelligence, and reporting and analytics services to global healthcare, pharma and biotech, life sciences, and medical devices companies. Our expertise extends to conducting insightful healthcare market research surveys and delivering in-depth and timely data to equip businesses to make informed decisions and navigate the dynamic healthcare industry landscape.
Explore new idea/opportunity – strategic insights.
Strategic research insights pave the way for building your future-oriented strategy …..
A solid marketing strategy development requires thorough evaluation and development…..
Performance insights play an integral role in driving brand strategy enabling ….
Efficient decision-making requires insights and the efficiency of the insights is directly proportional…..
Quick links.
Case Studies
Press Corner
Awards and Affiliations
Privacy Policy
© 2024 Borderless Access Pvt Ltd. All Rights Reserved.
[email protected]
What sets sis apart as a world-class healthcare market research firm, a healthcare market research firm offers invaluable data and analysis, helping businesses understand market trends, regulatory changes, and competitive dynamics..
SIS has over 40+ years of experience catering to the specific needs of the biggest names in the healthcare industry.
We provide critical physician and patient, physician, and stakeholder feedback regarding their medical products and services. Our robust network of accessible physicians, clinicians, nurses, dentists, chiropractors, acupuncturists, therapists, and paraprofessionals gives us real-world medical data. We probe the thoughts and opinions of medical professionals where they work, accessing the most applicable data and mining the crucial opinions of those who matter most where research is concerned.
With access to the widest demographic pool of respondents around the world, we are ready and able to communicate with the people most directly affected by and reliant on the healthcare industry for daily care, improved quality of life, and in many instances, for survival itself. We respect the importance of healthcare marketing research, and we take it seriously.
Partnering with a healthcare market research firm like sis helps businesses identify emerging opportunities, mitigate risks, and develop strategies that ensure long-term success..
SIS International stands out as a world-class healthcare market research firm for several reasons. Our comprehensive approach, deep industry expertise, and commitment to delivering actionable insights make us a trusted partner for businesses in the healthcare sector. Here’s what sets us apart:
At SIS , we utilize a multifaceted approach to healthcare market research. Our methodologies include qualitative and quantitative research, competitive analysis, and advanced data analytics. This holistic approach ensures we capture a complete market picture, providing our clients with detailed and actionable insights.
Our team of experts brings extensive experience in the healthcare industry, covering various specialties, including pharmaceuticals, medical devices, biotechnology, and digital health. This deep industry expertise enables us to provide insights that are not only data-driven but also contextually relevant and actionable.
At SIS International, we are committed to delivering insights that our clients can act upon. We go beyond data collection and analysis to provide strategic recommendations that drive business success. Our reports and presentations are designed to be clear, concise, and directly applicable to our clients’ business objectives.
With a presence in key global markets, SIS International offers a unique blend of global reach and local insights. Our extensive network of researchers and industry experts allows us to conduct research in diverse markets, providing our clients with a comprehensive understanding of global trends and local market dynamics.
At SIS International, we are committed to staying at the forefront of market research methodologies and technologies. We continuously invest in new tools, techniques, and training to enhance our research capabilities and deliver the highest-quality insights to our clients.
Hiring a top healthcare market research firm like sis international offers numerous benefits, including expert insights, comprehensive market analysis, customized research solutions, and enhanced strategic planning..
Digital health, or health tech, uses technology to improve the delivery of care and enhance consumption and payment for care. Health tech is useful for subsectors such as insurance, hospitals, and practitioners. It is also essential to pharmaceuticals, consumer-facing services, and government sectors. The potential of the partnership between health and technology is clear.
The healthcare industry has faced many scientific breakthroughs over the past few years. One of the major trends disrupting the industry is smart technology. It enables smooth functioning and reduces hospital administrators’ tedious work. The Internet of Medical Things is another disruptor. The IoMT incorporates medical devices and applications. It allows the transfer of medical information over secure networks. The third disruptor is tele-health. This is a combination of document sharing, mobile technology, and teleconferencing.
Healthcare market research firms provide valuable insights and support to a wide range of stakeholders.
Healthcare market research firms provide valuable insights and support to a wide range of stakeholders within the healthcare industry. These stakeholders include pharmaceutical companies, medical device manufacturers, healthcare providers, payers, investors, and more. Here are the key groups that can benefit from engaging with a healthcare market research firm:
Pharmaceutical companies require a healthcare market research firm like SIS to understand the competitive landscape, regulatory requirements, and market demand for their products. This research helps them navigate the complexities of drug development, optimize their product pipelines, and develop effective market entry strategies. For example, a pharmaceutical company launching a new drug can use market research to assess potential market share, competitive threats, and healthcare provider preferences.
Medical device manufacturers rely on market research to guide the development and commercialization of their products. This includes understanding healthcare provider needs, regulatory standards, and market trends. A top healthcare market research firm helps these manufacturers ensure that their devices meet market demands, comply with regulatory requirements, and achieve successful adoption.
Healthcare providers, including hospitals, clinics, and individual practitioners, benefit from healthcare market research firms by gaining insights into new treatments, technologies, and patient preferences. This research helps them make informed decisions about adopting new products and services, improving patient care, and optimizing clinical practices.
Payers and insurance companies use market research to evaluate the cost-effectiveness and potential savings associated with new healthcare products and services. This research informs their coverage decisions, reimbursement policies, and formulary placements. By understanding the economic impact of new treatments, payers can make informed decisions that promote patient access to affordable and effective healthcare solutions.
Investors and financial analysts rely on market research to evaluate the potential risks and returns associated with investing in healthcare companies. Healthcare market research firms provide insights into market dynamics, competitive positioning, and growth prospects, helping investors make informed investment decisions.
Biotechnology companies developing biologics and other advanced therapies require market research to understand industry trends, stakeholder perspectives, and the impact of new technologies. This research helps them innovate and develop cutting-edge solutions that meet the needs of the healthcare market.
CROs involved in the clinical development of new treatments need market research to understand regulatory requirements, competitive landscapes, and patient recruitment challenges. A world-class healthcare market research firm helps them design and conduct successful clinical trials that meet the needs of their clients and regulatory agencies.
Health technology companies developing digital health solutions, such as telemedicine platforms, health apps, and wearable devices, benefit from market research by understanding user needs, regulatory requirements, and market trends. Healthcare market research firms support them in developing innovative solutions that improve patient care and enhance healthcare delivery. For example, a company developing a new wearable health device can use market research to understand user preferences, regulatory standards, and potential market demand.
Patient advocacy groups engage with healthcare market research firms to understand patient needs, preferences, and treatment outcomes. This research helps them advocate for policies that promote patient access to affordable and effective healthcare solutions.
The importance of focus groups.
Focus Groups are becoming a central means of conducting qualitative research in healthcare. They allow researchers to collect data about participants’ beliefs and give insights into their opinions and values. Focus groups are well-suited for uncovering unmet patient and practitioner needs and identifying new areas of opportunity.
This type of research can help health professionals develop education programs. These programs have become important as more countries embrace cultural diversity. They also help researchers better understand the needs of minorities. Focus Groups are a boon for other vulnerable groups facing disparities in healthcare.
SIS International conducts Focus Groups with physicians, key opinion leaders, and specialists. We also convene groups for procurement managers, hospital administrators, and chiefs of staff. We serve C-suite hospitals and medical device executives. Our services are also for patient care coordinators and caregivers.
Focus Groups have gone online, providing benefits such as saving time in a busy world. They allow patients to connect over vast geographies, as many participants receive treatments that limit their mobility. Another benefit is that participants feel more comfortable at home, thus being more likely to open up.
The online Focus Group offers access to respondents from marginalized and understudied populations. This access is critical when researching diseases with low incidence rates. Online Focus Groups often have advanced analytics built into the platforms that provide further in-depth analysis of responses.
A Focus Group enables healthcare providers to gauge consumer response. Focus Groups offer instant ideas for the enhancement of certain products or concepts. They also help to pinpoint the product requirements of the end-user. They alert providers to other needs that they are not addressing. Other benefits include:
SIS International offers Quantitative, Qualitative, and Strategy Research. We provide data, tools, strategies, reports, and insights for decision-making. We also conduct interviews, surveys, focus groups, and other Market Research methods and approaches. Contact us for your next Market Research project.
Subscribe to our newsletter.
SIS International is a leading provider of Customer Insights, Market Research, Data Collection & Analysis, and Strategy Consulting.
Privacy Policy
Register for Focus Groups
Participate in Focus Groups
+1 917 536 0640
© 2024 SIS International Market Research
Physician Recruitment | In-Depth Interviews | Quantitative Surveys Obtain data and insights from the right respondents, eliminating guesswork and ensuring reliable results.
To ensure successful healthcare market research, it’s crucial to gather trustworthy opinions, reliable insights, and genuine feedback from actual users of your medical devices or pharmaceutical products.
With our services, you can avoid wasting valuable time, money, and resources on unsuitable matches and low-quality respondents. We provide high-quality, relevant feedback, enabling you to move forward with confidence in your product development efforts.
Healthcare Areas of Expertise
Interviews with KOLs, Physicians and HCPs Conducted
New Therapies and Devices Evaluated
Our Services
How We Help Healthcare Companies Reach Their Full Potential
Your medical device or healthcare product deserves precise and insightful feedback from the right medical experts, specialists, and patients. The quality of your research is directly linked to the quality of your respondents.
The outcome? Reliable, high-quality feedback from those who will actually use and benefit from your product. This empowers you and your team to make well-informed decisions with confidence.
Entering a market and maximizing the adoption of your medtech or pharma product requires more than guesswork. We’re here to provide clarity, ensuring your next steps are clear and confident.
From concept to launch, stay ahead of the competition and reach your full commercial potential with our data-backed strategy and extensive healthcare industry experience. Eliminate guesswork and move forward with full speed and confidence.
Choosing the wrong kind of research can delay your progress by years. That’s why we provide high-quality data to clarify your next steps. Our proven quantitative research methods will guide you confidently in the right direction.
Whether you’re looking to reduce development time, expedite FDA approval, or launch a new product to increase market share, our research provides the answers you need to make informed, forward-moving decisions.
Over 20 Years of Guiding Better Decisions in MedTech and Pharma
Partnering with You for Success
We believe in building strong relationships with our clients , working closely to achieve the best outcomes. We avoid outsourcing critical work or cutting corners, ensuring we fully understand your product, situation, and goals.
Dedicated to the Healthcare Sector
Executing a reliable healthcare market research plan requires experienced professionals who understand the significance of your work. Our team includes seasoned MD physicians and PhD scientists with extensive backgrounds in pharmaceuticals, medical devices, and biomedical industries.
Their expertise spans various therapeutic areas and medical specialties, ensuring you get real answers and results to move your company forward.
What Our Clients Say
“A phenomenal team I would recommend to anyone looking for actionable market and customer insights in healthcare. Our go-to market research partner.”
SENIOR CONSULTANT, Wilmington, DE
“KOLgroups is a trustworthy partner for our healthcare market research projects. We have partnered with them quite a few times and I count on them for our TDI/IDI needs.”
SENIOR DIRECTOR, Reason Research, Philadelphia, PA
“From 0 to 11 qualified respondents in 2 days! Crazy! I just can’t thank you enough for saving our research! We are thinking Boston in November for more research!”
DIRECTOR, Just Worldwide, Guildford, UK
Read Our Latest Posts
Medical Devices
September 11th , 2019
Medical Device Development in this Century
Developing a new medical device is a long and arduous process. It is one to which you must dedicate enough time as well as the financial resources for materials and personnel. While it can feel tempting to cut corners at the ....
By Craig W. Stropkay, PhD
August 19th, 2019
The challenges start-ups face to gain medical device approval
Getting a new medical device onto the market in the United States can be a drawn-out experience and one that can be frequently be difficult and time-consuming. It requires a great deal of knowledge about FDA submission ...
Get Expert Assistance for your Healthcare Market Research Project
Connect with the right physicians and medical experts so you get the opinions you need. We’ll eliminate the confusion, uncertainty, and chaos that often comes along with healthcare market research if not properly executed.
We illuminate micro and the macro views alike.
Reaching the heights is easier with a framework.
Research strong enough for offense and defense.
For a small outfit, we have impressive global reach.
Do your customers receive all you are transmitting? Let us help you find out.
Digging through data as if nothing else matters.
Don't let our size fool you.
Your business.
Where We Play
Oncology and Hematology
CV & Metabolic Disorders
Psychiatric/CNS Disorders
Ped + Adult Vaccines
Pain Management Respiratory Disorders
Infectious Disease
Women's Health
Ophthalmology
Rare Diseases
Market Landscape
Positioning/Repositioning
Lexicon & Natural Language
Demand & Patient Optimization
ATU/Tracking + KPIs Emotional Drivers
Segmentation
Messaging & Story Flow
Product Concept Tests/TPP
Patient Journey
Since its 2014 inception, Armature has conducted research in more than 30 countries (on 6 continents). Read on to see why half of the world's Top 20 pharma companies have trusted Armature with their market research challenges
Areas of Excellence
Choice Models
Demand Studies
ATU/Tracking + KPIs
Emotional Drivers Buying Process
Armature's overriding goal is to produce actionable research that goes beyond expectations and reveals the reality of the market. Whether your focus is HCPs, Patients, or Caregivers, we find you better answers with deep roots in high-quality data.
We customize our approach to each challenge we encounter. We come to the table without preconceptions and use the best methods to tackle the situation. If we don't have the "best methods" on hand, we build them for you.
At Armature we use best practices not as our goal, but as a springboard into even better work. We listen. We ask good questions. We listen some more. And we are always thinking about how to deliver best practices plus .
The term "armature" means several things, among them a strong supporting foundation or protection from attack . In art, it provides structural support for a sculpture or figure--what some call a "wireframe." Armatures are also the specific parts in electric motors where electricity gets generated.
You may not be used to a market research partner who manages to bundle strong insights with a hint of electricity as well. But it's time for your team to experience it.
Life Sciences is in hyperdrive. The breakneck pace of innovation is saving millions of lives. Yet many challenges remain the same. How to balance the needs of patients and providers with the demands of regulators and stakeholders? How to lead with science while listening to human experience? Escalent’s deep healthcare and life sciences insights and agile implementation model help the innovators of today become the market leaders of tomorrow.
Expect the gold standard in life sciences consulting and healthcare market research.
Escalent is a leading, global life sciences and healthcare market research and consulting firm . We know the players, the trends, and the policies that drive change across the health ecosystem. From big pharma ceutical compan ies to small biotech. From medical suppliers and device manufacturers to hospitals and healthcare providers.
The leaders of tomorrow need a holistic life sciences consulting partner. We support clients across the entire product lifecycle—from pre-clinical innovation to commercialization and post-launch tracking. You can expect seasoned medical consultants, data scientists, and insights practitioners with a passion for your industry. Let us help you accelerate the development process from molecule to brand launch and beyond.
Staying on top means juggling multiple priorities. Where can you expand, what challenges will you face, and how will you succeed? We partner with growing healthcare firms to deliver nuanced market assessments, competitive intelligence, and M&A support. Whether it’s quick-turn intelligence or ongoing monitoring, find out where to play and how to win with innovative healthcare and life sciences market research and consulting from Escalent.
Life sciences and healthcare are facing significant changes, from meeting patient needs to developing new treatments. Escalent is behind the household names known for trusted care—our healthcare and life sciences market research and analysis defines, shapes and evaluates your brand and our strategies optimize your messaging on a personal level to make powerful connections with patients and HCPs. Let us help future proof your most powerful asset.
Innovation is the name of the game in life sciences and healthcare. Escalent partners with the world’s largest healthcare and pharmaceutical companies, leveraging market research to identify the next big opportunity—whether it’s evaluating and prioritizing novel assets or understanding epidemiology. Clients rely on our healthcare insights, strategy, consulting and implementation expertise to position them for success.
Facing tight timelines but your team is consumed by non-core tasks? Trying to stay on top of the latest innovations? Escalent provides a dedicated team of Implementation Consultants as researchers and analysts to provide ongoing support. We act like an extension of your team without the headaches of headcount approval, hiring, onboarding, or training. Work smarter and move faster with Escalent.
The growing competition in the life sciences industry makes customer and patient centricity essential for brands. Find out how brands can fuel customer centricity by diving deep into doctor, patient, and HCP behavior and their journey across multiple touchpoints.
The customer journey is evolving. Download our guide to boosting customer growth using its award-winning path-to-purchase research.
In a recent discussion amongst industry peers, we examined why trust is so crucial, how it can be measured, and the challenges and opportunities it presents in the pharma and healthcare industries.
Top data analytics and advisory firm Escalent announces it has acquired C Space and Hall & Partners.
Escalent's Tech TrustBuilder is a scientifically-validated framework that measures trust in technology to help brands build bonds with people
Escalent's ISO/IEC 27001 certification is one way we maintain rigorous vigilance on the global regulatory landscape
Keep me informed. I’d like to receive occasional newsletters, event notifications, and thought leadership materials.
17430 College Parkway Livonia, MI 48152
P: +1 734 542 7600
©2024 Escalent and/or its affiliates. All rights reserved. Reg. U.S. Pat. & TM Off
by The Editorial Team at Plunkett Research, Ltd. , on July 30, 2024
This article explores the most significant trends affecting the consulting industry, drawing on insights from a recent industry report by Plunkett Research.
The consulting industry is at the forefront of technological advancements. Key areas such as artificial intelligence (AI), automation, data analytics, and cybersecurity are revolutionizing how consulting firms operate and deliver value to clients. For instance, generative AI is enhancing consultants' ability to conduct research, create presentations, and complete projects more efficiently, ultimately boosting profitability.
Information technology (IT) consulting continues to be a major growth driver. The sector encompasses a wide range of services, including e-commerce, telecommunications, cloud computing, and mobile app development. The shift towards cloud-based solutions and the Internet of Things (IoT) is creating new opportunities for IT consultants.
Management consulting remains a vital part of the industry, focusing on helping organizations improve efficiency, productivity, and profitability. Key areas include strategy development, organizational restructuring, and mergers and acquisitions.
The consulting industry is increasingly global, with significant growth opportunities in emerging markets. Countries like India, Brazil, and China are becoming important hubs for consulting services.
Consulting firms are adopting innovative business models to meet changing client demands and enhance profitability. Key trends include contingency-based pricing, the integration of digital advertising services, and the rise of internal consulting units.
Healthcare and government sectors present substantial opportunities for consulting firms, driven by regulatory changes, technological advancements, and the need for improved efficiency.
Robotic Process Automation (RPA) and generative AI are reshaping the consulting landscape by automating routine tasks and enhancing consultants' capabilities.
The consulting industry is becoming more competitive, with clients demanding tangible returns on investment and more flexible engagement models.
The consulting industry is poised for continued growth and transformation. For investors, consultants, and marketing professionals, staying abreast of these trends is essential for capitalizing on new opportunities and maintaining a competitive edge. Whether it's leveraging AI and data analytics, expanding into emerging markets, or adopting innovative business models, the future of consulting promises to be dynamic and full of potential.
Use this report to quickly understand major industry trends, access key consulting industry statistics, and gain an understanding of top competitors in this space. Visit the report page using the link above to learn more.
Plunkett Research, Ltd. is a leading publisher of business and industry research, with a global client list of top corporations, consultancies, investment firms, universities and government agencies. Our core focus is on the analysis of industry trends, industry benchmarks, technologies and opportunities. This allows us to leverage our research methodology to deliver accurate, timely information that our clients need to develop business strategies, determine market scope and consider investment opportunities.
With Permission Copyright © 2024, Plunkett Research, Ltd., All Rights Reserved
Our goal is to help you better understand your customer, market, and competition in order to help drive your business growth.
Posts by topic.
MarketResearch.com 6116 Executive Blvd Suite 550 Rockville, MD 20852 800.298.5699 (U.S.) +1.240.747.3093 (International) [email protected]
Subscribe to blog, connect with us.
According to latest report, the global healthcare contract research organization (CRO) market size was USD 52.19 billion in 2023, calculated at USD 55.95 billion in 2024 and is expected to reach around USD 104.60 billion by 2033, expanding at a CAGR of 7.2% from 2024 to 2033. North America dominated the healthcare contract research organization market with the largest revenue share of 38% in 2023.
Contract Research Organizations (CROs) are integral to the drug development process, offering a full range of services that span every phase of clinical trials. They play a crucial role in developing robust study protocols, ensuring scientific rigor from trial inception. CROs employ effective strategies for patient identification and enrollment, critical for meeting trial objectives.
The Full Study is Readily Available | Download the Sample Pages of this Report@ https://www.novaoneadvisor.com/report/sample/6458
Market Overview
The healthcare contract research organization market is experiencing rapid growth driven by increasing demand from pharmaceutical , biotechnology , and medical device industries. CROs specialize in providing a comprehensive array of services essential for clinical trials , including regulatory affairs, clinical trial planning, site selection and initiation, recruitment support, clinical monitoring, data management, trial logistics, biostatistics, medical writing, and project management. These services are crucial for managing and executing clinical research studies efficiently, supporting product development from inception to market approval. CROs play a pivotal role in navigating complex regulatory landscapes and ensuring adherence to ethical standards, safeguarding the rights and well-being of study participants. Their expertise and ability to streamline processes contribute significantly to the market’s growth by enabling efficient and compliant clinical trial operations across global healthcare sectors.
· In February 2024, European CRO FGK expanded into the UK through the acquisition of Clinicology.
· In July 2023, Catalyst Clinical Research announced the acquisition of Genpro Research.
· In August 2023, Kohlberg signed a definitive agreement to acquire a majority stake in Worldwide Clinical Trials.
Immediate Delivery is Available | Get Full Report Access@ https://www.novaoneadvisor.com/report/checkout/6458
U.S. Healthcare Contract Research Organization (CRO) Market Size to Hit USD 27.44 Bn by 2033
The U.S. healthcare contract research organization (CRO) market size was estimated at USD 13.95 billion in 2023 and is projected to hit around USD 27.44 billion by 2033, growing at a CAGR of 7.0% during the forecast period from 2024 to 2033.
North America stands as a leader in the healthcare contract research organization market, fueled by robust contributions from prominent companies such as IQVIA, known for its extensive service portfolio in clinical research advancement. Companies like ClaraHealth, with their patient-centric recruitment acceleration platform, play a pivotal role in enhancing CRO operations across the US and globally. In Canada, the pharmaceutical industry’s focus on innovation is pivotal, aiming to broaden access to cutting-edge medicines, vaccines, and treatments nationwide. This collaborative effort is not only driving advancements in healthcare but also positively impacting communities throughout the region, reinforcing North America’s leadership in the global healthcare contract research organization market.
Asia Pacific emerges as the second most dominant region in the healthcare contract research organization market, driven by a robust network of specialized service providers facilitating comprehensive drug discovery and development programs for pharmaceutical and biotechnology companies. These include Discovery CROs, Pre-Clinical CROs, Clinical CROs, and those offering bioequivalence and bioavailability services. Outsourcing research and development activities to CROs allows companies to enhance operational efficiency and focus on core competencies. In China, the expansion of health insurance coverage to over 95% of the population reflects significant strides in healthcare accessibility, supported by decades of economic growth and rising personal incomes. This socio-economic progress has spurred increased demand for improved healthcare services, underscoring Asia Pacific’s pivotal role in driving growth and innovation within the global CRO market.
Report Highlights
The clinical monitoring segment stands out as a dominant force in the global healthcare contract research organization market. Effective clinical monitoring is pivotal for ensuring the success of clinical trials and accelerating the introduction of new drugs to market. This service involves meticulous oversight and assessment of trial activities, tailored to meet the unique requirements of each study. By providing comprehensive monitoring services, CROs play a crucial role in maintaining trial integrity, adherence to protocols, and regulatory compliance, thereby facilitating efficient and successful drug development processes for pharmaceutical and biotechnology companies worldwide.
The regulatory/medical affairs segment is poised for growth with a projected CAGR in the forecast period within the healthcare contract research organization market. Regulatory affairs has evolved as a critical profession aimed at safeguarding public health by regulating the safety and efficacy of various products, including pharmaceuticals, medical devices, and cosmetics. Governments enforce stringent regulations to ensure products meet quality standards, while companies strive to comply to maintain public trust and health benefits. As regulatory complexities increase globally, CROs specializing in regulatory affairs play a pivotal role in navigating these frameworks, offering expertise in compliance, submission processes, and strategic advice. This segment’s anticipated growth underscores its importance in facilitating regulatory compliance and supporting the successful development and market approval of healthcare products worldwide.
The clinical segment emerged as the dominant category in the global healthcare contract research organization market. CROs possess specialized knowledge, capabilities, and established processes essential for the successful development and execution of clinical trials, ensuring adherence to rigorous national and international standards. Partnering with a CRO equips pharmaceutical and biotechnology companies with innovative tools that enhance operational efficiencies, resulting in reduced trial timelines and costs. While clinical CROs focus on comprehensive trial management services, laboratory CROs specialize in drug discovery, manufacturing, and bioanalytical services, collectively bolstering the capabilities necessary for advancing medical research and therapeutic innovations on a global scale.
The pre-clinical segment is anticipated to experience the fastest growth during the forecast period within the healthcare contract research organization market. Pre-clinical research encompasses the crucial stages of development and testing that precede human trials, focusing on verifying the safety and efficacy of new products. This process involves meticulous protocol creation and initial research phases to assess product safety through animal studies. Pre-clinical studies play a pivotal role in evaluating the potential of therapeutic drugs or strategies before progressing to clinical trials, ensuring that only the most promising candidates advance to human testing. As demand for early-stage research continues to expand, CROs specializing in pre-clinical services are poised to play a pivotal role in accelerating drug development timelines and enhancing research efficiencies, thereby driving growth in the global healthcare contract research organization market.
By application:
The oncology segment is observed to grow at a notable rate in the healthcare contract research organization market. The rise of precision medicine, which tailors treatments based on individual genetic profiles, particularly in oncology, requires extensive data collection, analysis, and clinical trial support from specialized CROs. The complexity and rigorous regulatory requirements for oncology drugs necessitate specialized expertise and resources that CROs can provide, including navigating clinical trial design, patient recruitment, and compliance with regulatory standards. Innovations in cancer treatment, such as immunotherapies, targeted therapies, and personalized medicine, require extensive research and development, leading to a greater need for specialized CRO services.
Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/6458
Market Dynamics
Integral Support in Drug Development
Contract Research Organizations (CROs) contribute significantly to the healthcare sector by providing comprehensive services across drug development, laboratory operations, and lifecycle management. They offer essential pre-clinical drug development services such as pharmacology and toxicology testing, development of drug delivery devices, and conducting shipping tests. CROs specialize in data management, regulatory affairs, and quality assurance, ensuring compliance and efficiency throughout the drug development process. CROs play a crucial role in accelerating drug development timelines and reducing costs, particularly beneficial for small businesses. Their cost-efficient services compared to in-house development enable companies to expedite the evaluation of new drugs while mitigating expenses. This capability enhances the attractiveness of CROs, driving growth in the healthcare contract research organization market by supporting efficient and streamlined drug development processes.
Complex Regulatory Compliance
Complex regulatory compliance poses a significant restraint on the growth of healthcare Contract Research Organizations (CROs). CROs play a crucial role in managing regulatory affairs for clinical trials, ensuring compliance with intricate regulations and guidelines governing the industry. Their expertise and knowledge are essential in navigating these complexities to ensure that trials meet stringent standards and expectations. Rigorous regulatory environment can slow down operational timelines and increase costs, presenting challenges for CROs aiming to streamline processes and expand their market presence. Addressing these regulatory hurdles through enhanced efficiency and compliance strategies is essential for sustained growth in the healthcare contract research organization market.
Opportunity
Technology Transformation
Investing in digital technologies presents a significant opportunity for Contract Research Organizations (CROs) to enhance collaboration across the clinical trial ecosystem and elevate their leadership position. Technology integration enables CROs to streamline traditionally manual administrative tasks, improving trial success by enhancing transparency, controlling spending, accelerating start-up timelines, and generating cost savings for sponsors. This technological evolution not only drives operational efficiency but also strengthens the value proposition of CROs, positioning them to capitalize on the growing demand for streamlined and tech-enabled clinical trial services.
Browse More Insights of: Nova One Advisor
Healthcare Contract Development And Manufacturing Organization Market Size (USD 630.87 Billion) Report by 2033
Oncology Market Size (USD 521.60 Billion) Report by 2033
Pharmaceutical CDMO Market Size (USD 295.95 Billion) Report by 2033
Biopharmaceutical Market Size (USD 1,101.77 Billion) Report by 2032
Biopharmaceutical CMO And CRO Market Size (USD 65.36 Billion ) Report by 2033
Active Pharmaceutical Ingredient CDMO Market Size (USD 249.22 Billion ) Report by 2033
Cell And Gene Therapy CDMO Market Size (USD 69.11 Billion ) Report by 2033
Advanced Therapy Medicinal Products CDMO Market Size (USD 34.53 Billion ) Report by 2033
Biotechnology Market Size (USD 5.68 Trillion ) Report by 2033
Clinical Trials Market Size (USD 153.59 Billion) Report by 2033
Immediate Delivery Available | Buy This Premium Research
https://www.novaoneadvisor.com/report/checkout/6458
Healthcare Contract Research Organization Market Top Key Companies:
Healthcare Contract Research Organization Market Recent Developments
Healthcare Contract Research Organization Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Healthcare Contract Research Organization market.
By Services
By Application
Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.novaoneadvisor.com/report/checkout/6458
Nova One Advisor is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defines, among different ventures present globally.
Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818
Email: [email protected]
Web: https://www.novaoneadvisor.com/
Don't miss out
Subscribe to STAT+ today, for the best life sciences journalism in the industry
By Bob Herman Aug. 1, 2024
R 1 RCM is finally getting taken off the public markets, ending a months-long saga between private equity firms that were trying to take control of the large health care billing and collections company.
Private equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice are teaming up to buy R1 , the companies said Thursday. TowerBrook, in a partnership with the Catholic hospital system Ascension, already owns 36% of R1 — which made TowerBrook and Ascension the company’s largest combined shareholder. TowerBrook and CD&R are buying the rest of the company for $14.30 per share in cash, valuing R1 at $8.9 billion.
advertisement
The bidding war for R1 highlights private equity’s appetite for “revenue cycle management” companies, which run the medical billing, collections, patient registration, and other administrative services for hospitals and physician groups.
STAT+ Exclusive Story
Already have an account? Log in
Unlock this article — plus daily market-moving biopharma analysis — by subscribing to stat+..
Totals $468 per year
for 3 months, then $39/month
Then $39/month
Savings start at 25%!
Annually per user
$300 Annually per user
Get unlimited access to award-winning journalism and exclusive events.
Business of Health Care Reporter
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc. newsletter .
health care costs
Health insurance
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect
To submit a correction request, please visit our Contact Us page .
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
En Español (Spanish)
July 25, 2024
Through product testing conducted by the New York State Department of Agriculture and Markets and confirmed by the FDA, the FDA has determined that the ground cinnamon product listed below contains elevated levels of lead and that exposure to this product may be unsafe. The FDA is advising consumers to throw away and not to buy this ground cinnamon product.
Distributor | Retailers | Brand Names | Lot Codes | Lead Concentration (ppm) | Product Image |
---|---|---|---|---|---|
El Servidor Corp of Elmhurst, NY | Mannan Supermarket, Inc. | El Servidor | None | 20 |
The FDA has recommended that the distributor voluntarily recall this product. The FDA will update this notice with communication from the firm if they voluntarily agree to recall. Please see our initial alert on ground cinnamon products issued March 6, 2024, for a list of additional ground cinnamon products previously recommended for recall.
The FDA is continuing to analyze cinnamon and review sample results received from state partners who have been continuously sampling ground cinnamon at retail for elevated levels of lead. This public health alert will be updated as necessary if the FDA finds that additional products contain elevated levels of lead and that exposure to these products may be unsafe.
To report a complaint or adverse event (illness or serious allergic reaction), you can:
Based on FDA’s assessment, consuming this product is likely to contribute to elevated levels of lead in the blood, especially in babies and young children. Protecting children from exposure to lead is particularly important because they are more susceptible to lead toxicity. Most children have no obvious immediate symptoms. Parents and caretakers should consult a healthcare provider if you suspect a child may have been exposed to elevated levels of lead. Short term exposure to elevated lead could result in the following symptoms: headache; abdominal pain/colic; vomiting; anemia. Longer term exposure to elevated lead could result in the following additional symptoms: irritability; lethargy; fatigue; muscle aches or muscle prickling/burning; constipation; difficulty concentrating/muscular weakness; tremor; weight loss.
The potential for adverse health effects from consuming food contaminated with lead varies depending on the level of lead in the food; age of the consumer; length, amount, and frequency of exposure to lead in the food; and other exposures to different sources of lead. For example, the very young are particularly vulnerable to the potential harmful effects from lead exposure because of their smaller body sizes and rapid metabolism and growth. High levels of exposure to lead in utero, infancy, and early childhood can lead to neurological effects such as learning disabilities, behavior difficulties, and lowered IQ.
Good nutrition – like meeting the recommendations in the Dietary Guidelines for Americans – can help protect against the health effects from exposure to lead. Eating a variety of healthy foods can make it less likely for an individual to be exposed to the same contaminant from the same food many times and helps to provide the range of nutrients needed for health and, for children, healthy development. Having adequate nutrients stored in the body also can help to prevent lead from having harmful effects. To get adequate food variety, FDA recommends that consumers eat many different foods from the five food groups – vegetables, fruits, grains, dairy, and protein foods – and to alternate how often you provide the same food.
The FDA is advising consumers to throw away and not to buy the ground cinnamon product listed above because samples of this product were found to contain elevated levels of lead. Based on FDA’s assessment, exposure to this ground cinnamon product may be unsafe and could contribute to elevated levels of lead in the blood. No illnesses or adverse events have been reported to date in association with this product.
While ground cinnamon products may not be a food targeted to young children, cinnamon is used in many foods young children consume. Consistent with the agency’s Closer to Zero initiative , which focuses on reducing childhood exposure to lead, the agency is recommending voluntary recall of the product listed above because prolonged exposure to the product may be unsafe. Removing this product from the market will prevent it from contributing elevated amounts of lead to the diets of children.
The FDA is taking the additional step in issuing a second public health alert this year for ground cinnamon to ensure the safety of ground cinnamon used in foods that are frequently consumed by babies and young children. While a lead level of 20 ppm is significantly lower than the levels of lead associated with the WanaBana cinnamon apple puree and applesauce products recalled in the fall of 2023, which were between 2,270 and 5,110 ppm lead in the cinnamon, the agency considers this ground cinnamon product to be unsafe for consumption by all babies and young children.
During the last year, the FDA asked states to prioritize testing of ground cinnamon and other spices, prior to the recall of WanaBana apple puree and applesauce products containing elevated levels of lead and chromium. Following the FDA’s targeted assessment of ground cinnamon products for lead and chromium and the FDA public health alert issued earlier this year, several states provided the FDA with sampling data for samples of ground cinnamon. The New York State Department of Agriculture and Markets collected the sample included in this public health alert. The FDA is continuing to review sample results received from state partners who have been continuously sampling ground cinnamon at retail for elevated levels of lead and will update this alert as necessary if the FDA finds that additional products contain elevated levels of lead and that exposure to these products may be unsafe.
The FDA continues to work with states to test cinnamon sold directly to consumers at retail and to test cinnamon at import. The FDA will continue our activities at import to prevent unsafe cinnamon from reaching consumers in the U.S., including adding firms and products to import alerts where appropriate.
For ingredients and final products that contain cinnamon, the FDA advises both domestic and foreign food suppliers to voluntarily test their products to ensure safety. Ultimately, it is the responsibility of the manufacturers and the importers to ensure the safety of the products that enter into the U.S. market. In March 2024, the FDA sent a letter to cinnamon manufacturers, processors, distributors and facility operators in the U.S. reminding them of the requirement to implement controls to prevent contamination from potential chemical hazards in food, including in ground cinnamon products. The FDA will continue to work with firms to ensure they are meeting their responsibilities under provisions of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food rule .
The FDA is also continuing its Toxic Elements monitoring program, which includes testing of a variety of foods including colored spices offered for sale in the U.S. In addition to sampling, as part of the FY2025 Legislative proposal , the FDA is seeking to amend the Federal Food, Drug, and Cosmetic Act (FD&C Act) to expressly require industry to conduct testing of final products, including those marketed for consumption by infants and young children, for contaminants and maintain such records of these testing results for FDA inspection.
17 Generative AI Data Analytics Tools Everyone Should Know About
Thanks to generative AI, we’re getting close to the promise of truly “democratizing” data. This means anyone can make decisions that are data-driven, not just highly skilled data scientists.
Here ‘s the issue: The amount of data in the world is growing exponentially. And hidden within all of that information are insights that can potentially help us do anything from curing cancer and discovering new sources of clean energy, to improving our health and fitness and growing our businesses.
So the problem isn’t that we don’t have enough information do these things. It’s that we have too much, and don’t know the best place to start!
Traditionally, extracting insights and value from data required two things – very clever, highly trained people and lots of time.
Here, AI has proven very useful. For the past decade, we’ve used deep learning algorithms to crunch numbers far quicker than any human, spotting patterns and pulling out insights. It also allows us to find clues hidden in unstructured data, such as text, video and sound.
Now, generative AI can translate these insights into advice and instructions that anyone can easily understand, as well as create and interpret graphs, charts and statistics.
So here’s my roundup of what I believe to be the most useful tools for anyone wanting to apply generative AI to data analytics, whether they are an enthusiastic amateur or expert in the field.
The Alteryx platform now incorporates a no-code AI studio to let users create their own analytics apps using custom business data. Data can then be queried through a natural language interface, which includes access to models such as OpenAI’s GPT-4.
Why did the nfl change kickoff rules the ‘dynamic kickoff,’ explained, nyt ‘strands’ hints, spangram and answers for friday, august 2nd.
Built on its Alteryx AiDIN engine, the platform differentiates itself from competitors with a user-friendly approach to predictive analytics and insight generation. A key feature is its Workflow Summary Tool, which interprets complex workflows into simple-to-understand natural language explanations and summaries. You can also specify how you want your reports to be output, for example, in email or PowerPoint formats, to target your desired audience.
Overall, Alteryx is a great choice for analysts and SME users looking for an all-around platform for creating custom analytics apps and generating predictive insights.
Microsoft Power BI
This is an industry-standard analytics package that’s been enhanced with the power of generative AI, harnessing Microsoft’s Co-Pilot technology and models developed with OpenAI, including customized versions of its powerful GPT-4 models.
The platform integrates numerous technologies including Microsoft’s Fabric AI-powered analytics framework, as well as Azure Synapse which allows it to seamlessly integrate with data warehouse and other Big Data technologies like Apache Spark. This creates an end-to-end analytics solution suitable for the largest enterprise workloads, enabling anything from simple analytics to building and deploying your own machine learning models on Azure. It’s a good choice for enterprise users needing flexible cloud integrations and dealing with extensive data workloads.
Tableau Pulse
Tableau is one of the world’s most popular data visualization tools and now features Tableau Pulse, built on Salesforce’s Einstein models, for AI-powered insights. Its Insights Platform allows automated analysis of datasets, extracting insights and trends in natural language while also generating visualizations. The package is aimed at facilitating data-driven decision-making and improving productivity by giving business users access to in-depth analytics at their fingertips. Security and ethics are also important when working with data, So Salesforce has integrated its Einstein Trust Layer guardrails with Tableau Pulse for peace of mind in this respect. Ideal for decision-makers who want to create user-friendly and detailed visualizations.
Another established analytics and data platform that now lets users embed generative AI analytics content into their reports and dashboards through its Qlik Answers assistant. It features automated summaries of key data points, natural language reporting and a host of integrations with third-party tools and platforms. A particular emphasis is placed on explainability to ensure it is always able to support its insights with sources and citations. The Qlik platform is particularly useful for users who want to analyze large volumes of unstructured data like text or videos, and now, thanks to Qlik Answers, this can all be done with natural language.
Sisense now lets you embed conversational analytics directly into your BI tools and applications. This makes it simple to automate processes including data preparation as well as building analytics dashboards and reports. Sisense is a widely used platform with a user-base spanning research scientists to business analysts, and is designed to make analytics accessible to anyone, regardless of their level of expertise. This makes it a useful tool for anyone needing a powerful analytics engine that can be deployed quickly and efficiently.
New genAI-powered analytics tools are emerging practically every day. Here are some of the others that are worth taking a look at.
Generative BI platform that enables predictive modeling and insight generation.
Coefficient
Coefficient automates importing live data from platforms like Hubspot or Salesforce into Excel or Goole Sheets and can interface with ChatGPT to query your data in natural language.
Domo uses natural language conversations to guide you through the process of deploying analytics and extracting insights.
Generative AI Tools For Excel
The plugin provides custom connectivity with Excel for ChatGPT, Claude, and Gemini Pro.
Talk directly to your data to get expert insights and analysis alongside customized reports.
Microstrategy
Generative AI assistant provides quick answers and insights into business data.
MonkeyLearn
It specializes in the in-depth analysis of text information, such as customer feedback reports.
Answer your important business questions with instant insights using Polymer’s PolyAI chatbot.
Conversational data discovery and dashboard building with built-in security features, works with any LLM.
Generative AI analytics designed to provide marketing insights.
ThoughtSpot
AI-driven analytics platform that combines search and AI to enable natural language queries and automated insights generation.
YellowfinBI
Emphasizes data-driven storytelling and a collaborative approach to machine learning-powered analytics.
One Community. Many Voices. Create a free account to share your thoughts.
Our community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.
In order to do so, please follow the posting rules in our site's Terms of Service. We've summarized some of those key rules below. Simply put, keep it civil.
Your post will be rejected if we notice that it seems to contain:
User accounts will be blocked if we notice or believe that users are engaged in:
So, how can you be a power user?
Thanks for reading our community guidelines. Please read the full list of posting rules found in our site's Terms of Service.
The independent source for health policy research, polling, and news.
Jared Ortaliza , Jeannie Fuglesten Biniek , Elizabeth Hinton , Tricia Neuman , Robin Rudowitz , and Cynthia Cox Published: Jul 02, 2024
The largest private health insurance companies often offer plans in multiple markets, including the Medicare Advantage, Medicaid managed care, individual (non-group), and fully insured group (employer) health insurance markets. Each market has unique features, including eligibility, payment, and coverage rules, which affect insurers’ overhead and potential profit. In recent years, private insurers are playing a growing role in public insurance programs, with more than half of eligible Medicare beneficiaries enrolled in a private Medicare Advantage plan and nearly three-quarters of Medicaid enrollees obtaining coverage through a managed care plan (typically a private insurer).
This brief examines two measures of financial performance – gross margins and medical loss ratios – in the Medicare Advantage, Medicaid managed care, individual, and fully insured group health insurance markets using data reported by insurance companies to the National Association of Insurance Commissioners (NAIC) and compiled by Mark Farrah Associates, through the end 2023 (the most recent year of annual data).
In 2023, per enrollee gross margins were highest in the Medicare Advantage market, and medical loss ratios were lowest in the individual insurance market. While both gross margins and medical loss ratios are indicators of financial performance, higher margins and lower loss ratios do not necessarily translate into greater profitability since they do not account for administrative expenses or tax liabilities. Additionally, the increasingly complex structure of insurance companies, including the rise in consolidation and vertical integration, and role of subsidiaries, make it difficult to isolate the revenues and expenses associated with a particular insurance market. (A detailed description of each market is included in the Appendix).
Gross margins.
The gross margin per enrollee is the amount by which total premium income exceeds total claims costs per person over a specified time period (i.e., per year).
At the end of 2023, gross margins per enrollee ranged from $753 in the Medicaid managed care market to $1,982 in the Medicare Advantage market. Gross margins per enrollee in the group and individual markets were $910 and $1,048, respectively, roughly half the level observed among Medicare Advantage plans on average. The level of margins reflect, in part, the overall health needs and spending in a market segment. A similar margin in percentage terms will translate to a higher margin in dollars per enrollee when average health expenses are higher.
Another way to assess insurer financial performance is to look at medical loss ratios (MLRs), or the percent of premium income that insurers pay out in the form of medical claims. Generally, lower MLRs mean that insurers have a higher share of income remaining after paying medical costs to use for administrative costs or keep as profits. Each health insurance market has different administrative needs and costs, so a lower MLR in one market does not necessarily mean that market is more profitable than another market.
MLRs are used in state and federal insurance regulation in a variety of ways. In the commercial insurance (individual and group) markets, insurers must issue rebates to individuals and businesses if their MLRs fail to reach minimum standards set by the ACA. Medicare Advantage insurers are required to report MLRs at the contract level (which typically combines multiple plans) and are required to issue rebates to the federal government if their MLRs fall short of required levels and are subject to additional penalties if they fail to meet MLR requirements for multiple consecutive years. For Medicaid managed care organizations (MCOs), CMS requires states to develop capitation rates for Medicaid to achieve an MLR of at least 85%. There is no federal requirement for Medicaid plans to pay remittances if they fail to meet their MLR threshold, but a majority of states that contract with MCOs require remittances in at least some cases. The 2024 Consolidated Appropriations Act includes a financial incentive to encourage certain states to collect remittances from Medicaid MCOs that do not meet minimum MLR requirements.
The MLRs shown in this issue brief are simple loss ratios (claims as a share of premium income) and differ from the definition of MLR in the ACA and in Medicaid managed care , which makes some adjustments for quality improvement and taxes, and do not account for reinsurance, risk corridors, or risk adjustment payments.
In 2023, MLRs were similar across the group, Medicare Advantage, and Medicaid managed care markets and somewhat lower in the individual market. Simple loss ratios were around 84% in individual market, 86% in the fully insured (group) market, and 87% in the Medicaid managed care and Medicare Advantage markets.
While gross margins are not equivalent to profitability, changes in gross margins can be indicative of changes in profitability (assuming administrative costs and tax liability are stable). Across most markets, gross margins have been relatively stable in recent years, though they have declined somewhat from spikes that occurred in 2020 during the initial phase of the COVID-19 pandemic.
Medicare Advantage : Through the end of 2023, gross margins in the Medicare Advantage market averaged $1,982 per enrollee, which was similar to 2022 ($1,977), despite reports by the largest Medicare Advantage insurers of higher-than-expected utilization at the end of 2023. Potentially spurred by the prospect of strong financial returns, the Medicare Advantage market has grown substantially in the last decade, with more than 50% of eligible beneficiaries enrolled in a Medicare Advantage plan in 2023.
Group Market : Gross margins for fully insured group plans declined significantly from 2020 to 2021 (the lowest in the past decade) but have been increasing in subsequent years. In 2023, per enrollee gross margins in the group market were nearly the same as those in 2018.
Individual Market : Individual market gross margins were about 31% and 10% lower in 2023 than in 2018 and 2019, respectively. In 2018, following efforts to repeal the ACA and defunding of Cost Sharing Reduction subsidies, insurers raised individual market premiums substantially. These premium increases resulted in significantly higher margins than in earlier years (Figure 3).
Medicaid Managed Care : Per enrollee gross margins in the Medicaid managed care market decreased by 6% from 2022 to 2023 but remained higher than pre-pandemic levels. Starting in April 2023, pandemic-era policies that allowed for “continuous enrollment” in Medicaid ended and states began reviewing eligibility and disenrolling individuals who were no longer eligible or who did not complete the renewal process. National data show total Medicaid/CHIP enrollment declined by more than 9% (about 9 million people) from March 2023 to December 2023. Medicaid managed care plans expected the overall risk profile (or “acuity”) of its members to worsen during unwinding, as they anticipated “stayers” would be sicker than “leavers,” which may have contributed to the decrease in per enrollee gross margins seen from 2022 to 2023. States may use a variety of risk mitigation strategies to provide financial protection and limits on financial risk for states and plans that may not be accounted for in the data used in this analysis. Many states implemented COVID-19 related risk corridors (where states and health plans agree to share profit or losses) allowing for the recoupment of payments made for 2020, 2021, and 2022. Gross margins reported may not reflect recoupments of funds that may occur after the reporting period.
Each health insurance market has different administrative needs and costs, so similar MLRs do not imply that the markets are similar to each other in profitability. Additionally, simple MLRs examined in this brief do not incorporate the effects of changes in tax law, such as the health insurer tax, which has been permanently repealed starting in 2021, was in effect in 2018 and 2020, but was not in 2019. While MLRs alone cannot convey whether a market is profitable in a particular year, if administrative costs hold mostly constant from one year to the next, a change in the MLR could imply a change in profitability.
Individual Market : The average individual market MLR in 2023 was lower than in 2021 and 2022 but higher than those seen in the years leading up to the pandemic. As mentioned earlier, 2018 and 2019 were exceptionally lucrative years for the individual market. Many plans fell short of the ACA’s MLR requirements and were therefore required to issue large rebates to consumers based on their 2018 and 2019 experience.
Group Market : The average MLR for group plans was stable between 2022 and 2023 at 86%, and slightly below the average of 88% in 2021. These are all higher than previous years, when MLRs ranged from 83% in 2018 and 2020 to 85% in 2019.
Medicaid Managed Care : Relative to 2022, the average MLR in 2023 for the Medicaid managed care market increased slightly from 86% to 87% (implying a potential decrease in profitability) but remained lower than in 2018 and 2019. State Medicaid programs and managed care plans continue to be in a period of heightened uncertainty as unwinding continues. States and plans will be closely monitoring disenrollments and “churn” (off and on the program) as well as new utilization and acuity trends.
Medicare Advantage : Average MLRs in the Medicare Advantage market have been relatively stable over the last few years, averaging 87% in 2021 and 2023 and 86% in 2022. That is somewhat higher than before and during the onset of the COVID-19 pandemic. The slight increase of the MLR in the Medicare Advantage market could imply decreased profitability. It is also possible that some Medicare Advantage insurers opted to offer new or more generous extra benefits, such as over-the-counter allowances, meals following hospital stays, or transportation, in addition to gym memberships, dental, vision and hearing benefits that are offered nearly universally to help retain and attract new enrollees, while also ensuring that those at risk of falling below the required thresholds would have sufficient costs to avoid triggering any rebates to the federal government. At the same time, it may be difficult to interpret changes in MLRs with increasing consolidation, driven in part by insurers purchasing related businesses, such as pharmacy benefit managers, physician groups, and post-acute care providers, because it is not entirely clear how insurers allocate expenses across different lines of business.
Medicare Advantage plans have both higher average costs and higher premiums (largely paid by the federal government), because Medicare covers an older, sicker population. So, while Medicare Advantage insurers spend a similar share of their premiums on benefits as other insurers in other markets, the gross margins described above—which include profits and administrative costs—tend to be higher in Medicare Advantage plans.
This work was supported in part by Arnold Ventures. KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.
We analyzed insurer-reported financial data from Health Coverage Portal TM , a market database maintained by Mark Farrah Associates, which includes information from the National Association of Insurance Commissioners (NAIC). We used the “Exhibit of Premiums, Enrollment, and Utilization” report (accessed May 28, 2024) for this analysis. The dataset analyzed in this report does not include California HMOs regulated by California’s Department of Managed Health Care. Additionally, for Medicaid, there are five states (Arizona, California, Delaware, New York, and Oregon) that have different reporting practices and therefore consistently only have partial or no NAIC data available.
We excluded plans that were not present in the NAIC demographics file, filed negative values in any of the segments of interest, or have negative or zero dollars in premiums or claims. We also excluded plans reporting at least 1,000 hospital patient days incurred per 1,000 member months. We only included plans that were categorized as having a “medical” focus in our analysis and exclude “specialty” plans which are categorized as “ancillary or supplemental benefit plans.” We also excluded any plans from the U.S. territories. We corrected for plans that did not file “member months” or filed a zero “member month” value in the annual statement but did file current year membership by imputing these values. If, after imputing, plans still did not have “member months,” they were excluded.
The group market in this analysis only includes fully insured plans. NAIC defines “Medicaid” as “business where the reporting entity charges a premium and agrees to cover the full medical costs of Medicaid subscribers.” This explicitly excludes Administrative Services Only (ASO) plans. We only use “medical” focused plans to help exclude any specialty plans; however, prepaid ambulatory health plans (PAHPs), prepaid inpatient health plans (PIHPs), or Programs of All-Inclusive Care for the Elderly (PACE) plans may be included in the analysis due to NAIC’s definition of Medicaid.
Gross margins per enrollee were calculated by subtracting the sum of total incurred claims from the sum of unadjusted health premiums earned and dividing by the total number of members.
Premiums for Medicare Advantage plans primarily consist of federal payments made to plans and any additional amounts plans may choose to charge their enrollees. Premiums for Medicare Advantage plans do not include payments for Medicare Part D benefits. Premiums for Medicaid do not reflect contractual adjustments related to risk corridors or other risk-sharing adjustments.
To calculate medical loss ratios, we divided the market-wide sum of total incurred claims by the sum of all unadjusted health premiums earned. MLRs in this analysis are simple loss ratios and do not adjust for quality improvement expenses, taxes, or risk program payments. It should be noted that other organizations and agencies use claims and premiums reported in the “Statement of Revenues & Expenses” for their medical loss ratio calculations.
Individual Market :The individual market, which accounted for about 18 million people in the first quarter of 2023, includes coverage purchased by individuals and families through the Affordable Care Act’s exchanges (Marketplaces) as well as coverage purchased directly off-exchange, which includes both plans complying with the ACA’s rules and non-compliant coverage (e.g., grandfathered policies purchased before the ACA went into effect and some short-term plans). The federal government provides subsidies for low and middle-income people in the Marketplace and includes measures, such as risk adjustment, to help limit the financial liability of insurers. Insurers in the individual market receive premium payments from enrollees, plus any federal subsidies for people in the Marketplaces.
Some plans submitting data on the Exhibit of Premiums Enrollment and Utilization appear to be including some Children’s Health Insurance Program (CHIP) data in their Individual market filings. In a previous version of this analysis, we used the Supplemental Health Care Exhibit to address this. However, in this analysis, we opted to use the EPEU to ensure comparability.
Group Market :The fully insured group market serves employers, their employees and dependents who are enrolled in fully insured health plans. This market includes both small and large group plans but excludes employer-sponsored insurance plans that are self-funded, which account for 65% of workers with employer-sponsored insurance in 2023. Roughly 30 million people were enrolled in fully insured group market plans in 2023. Plans typically receive premium payments from both employers and their employees.
Medicaid Managed Care :The Medicaid managed care market includes managed care organizations (MCOs) that contract with state Medicaid programs to deliver comprehensive acute care (i.e., most physician and hospital services) to enrollees. As of July 2021, about three-fourths (just over 66 million people) of all Medicaid beneficiaries nationally received most or all of their care from comprehensive risk-based MCOs. There is significant variation across states with respect to services that are covered by MCOs.
In this analysis, the NAIC data we use defines “Medicaid” as “business where the reporting entity charges a premium and agrees to cover the full medical costs of Medicaid subscribers” and only explicitly excludes Administrative Services Only (ASO) plans from their reporting. While we only use “medically” focused plans to help exclude any specialty plans, PAHPs, PIHPs and PACE plans may not be excluded due to NAIC’s definition of Medicaid. Additionally, for Medicaid, there are five states (Arizona, California, Delaware, New York, and Oregon) that have different reporting practices and therefore consistently only have partial or no NAIC data available. In other work, KFF defines comprehensive MCOs as managed care plans that provide comprehensive Medicaid acute care services and, in some cases, long-term services and supports as well. This excludes “limited benefit plans” including prepaid ambulatory health plans (PAHPs), prepaid inpatient health plans (PIHPs), and Programs of All-Inclusive Care for the Elderly (PACE) that may be included in this analysis.
Mark Farrah Associates Health Coverage Portal TM includes data from fully capitated risk-based MCOs as well as non-comprehensive Primary Care Case Management (PCCM) plans and some specialty plans. PCCM plans have lower capitated payments than comprehensive MCO agreements because a primary care physician is paid a smaller flat fee for case management and care coordination responsibilities, but the remainder of services an enrollee receives are delivered on a Fee-For-Service agreement.
Medicare Advantage :The Medicare Advantage market provides Medicare-covered benefits through private plans to more than 30 million Medicare beneficiaries in 2023, which is just over half of all Medicare beneficiaries in 2023. The federal government makes risk-adjusted payments (higher payments for sicker enrollees and lower payments for healthier enrollees) to plans (averaging nearly $14,380 p er enrollee in 2023) to cover the cost of benefits covered under Medicare Parts A and B and supplemental benefits, such as dental, vision, hearing, and others, with additional payments for costs associated with prescription drug coverage. Some plans charge enrollees an additional premium.
Sellers are losing their advantage in the US housing market.
That's because higher levels of inventory are starting to weigh on home prices, the research firm Capital Economics said. It's starting to reverse a trend that's persisted for the past few years, with tight inventory pushing home prices to record highs .
US home prices notched another record in May, but the pace of growth cooled. Prices were up 5.9% on a yearly basis, down from the 6.4% recorded the prior month, according to the S&P CoreLogic Case-Shiller price index .
This is happening as housing inventory rises. Active house listings rose past 800,000 in the US in June, Realtor.com data shows. Meanwhile, nearly 65% of homes on the market are going at least 30 days without being contracted, a Redfin analysis found.
"Another moderate 0.3% m/m rise in house prices in May adds to the evidence that sellers are losing their grip on the market due to increasing supply," Thomas Ryan, a North American economist at Capital Economics, said in a note.
More inventory is good news for buyers, who have been limited by fewer options and inadequate housing supply . Home prices are already starting to fall in key metros , such as in the Sun Belt, where housing demand is especially weak, Redfin said in a previous note.
Related stories
But Capital Economics predicted home prices would continue climbing, forecasting a further 5% increase through year-end as a decline in mortgage rates boosts demand.
"It will take until 2025, or even 2026, for the market to become better balanced, where we have pencilled in price rises of 3% and 2.5% respectively," Ryan added. "Until recently, this had been an above-consensus forecast, but that is no longer the case."
IMAGES
VIDEO
COMMENTS
Find healthcare market research agencies that offer insights for providers and pharmaceutical companies. Browse by location, service, methodology, and more to locate the best fit for your needs.
Learn about the top healthcare market research agencies and their services, target clients, and geographic reach. Compare their features, pros, and cons in this comprehensive guide by Heartbeat.ai.
Our expert full-service health care market research team helps agencies and end clients ask the essential questions to deliver the business insights needed for strategic and tactical decision making that make a tangible impact. E-mail [email protected]. Phone 1-603-775-9200. www.qessential.com.
We are market research experts in the healthcare, pharmaceutical, device and diagnostics space, and have a wealth of experience in a wide range of therapy areas. Our scientifically grounded approaches deliver powerful, elevated insights that access the reality of the healthcare landscape, across the product life cycle. Learn More. HRW Shift.
Medscape Market Research offers custom research solutions to healthcare professionals using its large and engaged network of clinicians. It provides quantitative and qualitative studies, survey programming, recruitment, and data analysis services.
McKinsey offers insights on the changes and challenges facing the healthcare industry, covering topics such as digital transformation, AI, consumerism, and business models. Explore articles, podcasts, and collections on various aspects of healthcare systems, services, and technology.
iData Research provides procedure-based and brand-level market intelligence and consulting for the global healthcare industry. Learn how iData can help you grow your revenue and market share with customized solutions and data-driven insights.
At Magnolia Innovations, we specialize in providing insightful market research for the healthcare, pharmaceutical, and MedTech industries, aiding strategic decision-making and propelling businesses forward. ... Magnolia is a specialized market research consultancy to some of the world's most innovative healthcare companies. We find fresh ...
DelveInsight is a healthcare market research firm that provides reports and consulting services for Pharma and MedTech. Explore their portfolio of reports on various therapy areas and geographies, and get updates on EHA 2024 congress.
Optimize your economies of scale for market insights processes. Our knowledge services offer on-going insights generation through dedicated teams and specialist driven process. GRG's knowledge archives and specialized processes of delivery helps clients scale and optimize their marketing intelligence initiatives. Read More.
Top 15 Market Research Companies for Healthcare Providers. FSi (a division of Fresh Squeezed Ideas) $75,000+ $200 - $300 / hr 10 - 49 Toronto, Canada; Ability to deliver 29.6/40.0 15.8 Reviews; 8.5 Clients & Experience; 5.3 Market Presence; Service focus 40% Market Research ...
Adelphi Research is a global market research consultancy that inspires action and drives change, providing insights for pharmaceutical and healthcare.
Borderless Access Health provides world-class healthcare market research services, offering a synergy of primary market research, business intelligence, and reporting and analytics services to global healthcare, pharma and biotech, life sciences, and medical devices companies. Our expertise extends to conducting insightful healthcare market ...
A healthcare market research firm offers invaluable data and analysis, helping businesses understand market trends, regulatory changes, and competitive dynamics. SIS has over 40+ years of experience catering to the specific needs of the biggest names in the healthcare industry. We provide critical physician and patient, physician, and ...
Incorporated in 2011, Spade Health is a full-service healthcare market research company, specialized in healthcare market research, clinical data management, clinical research management, pharmaceutical market research, and medical market research. We have been empowering large and small companies to make informed decisions through market research.
To ensure successful healthcare market research, it's crucial to gather trustworthy opinions, reliable insights, and genuine feedback from actual users of your medical devices or pharmaceutical products. With our services, you can avoid wasting valuable time, money, and resources on unsuitable matches and low-quality respondents.
Armature's overriding goal is to produce actionable research that goes beyond expectations and reveals the reality of the market. Whether your focus is HCPs, Patients, or Caregivers, we find you better answers with deep roots in high-quality data.. We customize our approach to each challenge we encounter. We come to the table without preconceptions and use the best methods to tackle the situation.
Escalent is a leading, global life sciences and healthcare market research and consulting firm. We know the players, the trends, and the policies that drive change across the health ecosystem. From big pharmaceutical companies to small biotech. From medical suppliers and device manufacturers to hospitals and healthcare providers.
Our ever-expanding coverage spans over 86 specialties and 60 medical conditions in 57 countries. With in-house market research and analytics teams and a stakeholder coverage of more than 1.5 million healthcare professionals, we can conduct large-scale quantitative and qualitative research in hard-to-reach markets.
This report highlights 100 companies that generated at least $50 million in US healthcare staffing revenue in 2023. Added together, these firms generated $47.3 billion in such revenue, making up 88% of the market by our estimates. Report includes estimated 2023 healthcare staffing revenue and market share for each firm.
Obtain Additional Consulting Market Research. This article is an excerpt from a recent report titled Plunkett's Consulting Industry Almanac 2024, which covers competitive intelligence, market research and business analysis—everything you need to know about the global consulting industry.
According to latest report, the global healthcare contract research organization (CRO) market size was USD 52.19 billion in 2023, calculated at USD 55.95 billion in 2024 and is expected to reach around USD 104.60 billion by 2033, expanding at a CAGR of 7.2% from 2024 to 2033. North America dominated the healthcare contract research organization market with the largest revenue share of 38% in 2023.
R 1 RCM is finally getting taken off the public markets, ending a months-long saga between private equity firms that were trying to take control of the large health care billing and collections ...
The potential for adverse health effects from consuming food contaminated with lead varies depending on the level of lead in the food; age of the consumer; length, amount, and frequency of ...
Generative AI analytics designed to provide marketing insights. ThoughtSpot. AI-driven analytics platform that combines search and AI to enable natural language queries and automated insights ...
Table of contents for Journal of Marketing Research, 61, 4, Aug 01, 2024. Skip to main content. Intended for healthcare professionals ... governments and health authorities seek to publicize timely information about the pandemic. Yet social ... Restricted access Research ... firms, and society at large. Many online review platforms claim a ...
Individual Market: Individual market gross margins were about 31% and 10% lower in 2023 than in 2018 and 2019, respectively. In 2018, following efforts to repeal the ACA and defunding of Cost ...
Separately, Raymond James raised shares of Bausch Health Companies to a "hold" rating in a report on Wednesday, July 10th. Check Out Our Latest Analysis on Bausch Health Companies Bausch Health Companies Stock Performance. The company has a market cap of C$2.84 billion, a PE ratio of -4.30, a PEG ratio of 0.21 and a beta of 0.90.
Sellers are 'losing their grip' on the housing market as home prices cool, research firm says Jennifer Sor 2024-07-30T18:20:41Z
NEW DELHI, Aug 4 (Reuters) - India, which bans direct advertising of liquor, is set to announce sweeping rules that will bar even surrogate ads and sponsoring of events, which could force firms ...